Health
ESMO Guidelines Discourage Delayed, Discontinued Treatment During the COVID-19 Pandemic – OncLive
Any type of anti-cancer therapy that could impact overall survival should not be discontinued or delayed.
Any type of anti-cancer therapy that could impact overall survival (OS) should not be discontinued or delayed, according to a European Society for Medical Oncology (ESMO) interdisciplinary expert consensus paper on how to manage patients with cancer during the coronavirus disease 2019 (COVID-19) pandemic.1
The guidelines, which were recently published in the Annals of Oncology,2 also discourage classifying all patients with cancer as especially vulnerable to COVID-19, regardless of age, gender,…
-
General17 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News17 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
General19 hours agoPerth man charged after investigation into organised crime and tobacco store attacks
-
General24 hours agoCrowe toasts talkback titan for platforming ‘voiceless’